ADAMED Laboratorios SLU * Dedicated in body and mind.

Slides:



Advertisements
Similar presentations
UNDERSTANDING THE SITUTATION OF HEALTH CARE IN EASTERN EUROPE, ESPECIALLY IN THE FIELDS OF GIST Mr. Stefan Mandov – GIST Alliance for patients Bulgaria.
Advertisements

Research & Innovation Evolution from IMI1 to IMI2: challenges ahead Elmar Nimmesgern, PhD DG Research & Innovation 1.
Eli Lilly and Company – Tailored Therapeutics and Diagnostics © Eli Lilly and Company 2012 The views and opinions expressed herein and/or during the accompanying.
Patrick Vallance Head of Drug Discovery GlaxoSmithKline
Portugal Economic Evaluation Applied to Decision Making Isaura Vieira INFARMED, I.P. – National Authority for Medicines and Health Products I Pan-American.
Anah Khaja 2/27/13 Psychology Honors (1 st Period)
Value of information An innovative approach to prioritizing comparative effectiveness research AHRQ Annual Meeting September 29, 2010.
Update on a recently launched European R&D endeavour: The Innovative Medicines Initiative (IMI) FERS meeting Brussels, 7 th April 2008.
Have FDA Expedited Programs Shortened Drug Development Timelines? An analysis of newly approved therapies and how FDA expedited programs impacted drug.
Ethics, Values And Compliance in Pharma Business – The Need To Walk The Talk Tapan J. Ray Emprove Seminar Series November 21, 2014 Hyderabad.
The 5th Globelics Academy Ph.D. School on ‘ National Innovation Systems and Economic Development ’ 2–14 June, 2008, Tampere – Finland Nejla YACOUB Nejla.
 Broad-based health care company that discovers, develops, manufactures, and markets products and services  Abbott's main businesses: ◦ Global pharmaceuticals.
FOR THE DOCTORS OF TODAY & TOMORROW OVERVIEW Next Generation application Innovative, intelligent, simple and user friendly End to End solution Secured.
DAVID HARDING CPhI 2008 SHANGHAI JUNE 24–26, 2008 Product Selection for API Manufacturers and Generic Pharmaceutical Companies: A Tool for Success.
Jan 2009 INTRODUCTION TO JUBILANT FULLY INTEGRATED SOLUTIONS IN GENERICS.
Industry Trends and Tools for Generic Product Selection KATE KUHRT SHANGHAI JUNE 19-21, 2007.
The Pharmaceutical Industry. Industry introduction Opportunity How to get into this industry ?
* Dedicated in body and mind. “Instead of a passive waiting for what future will bring us, we belive in a possibility of creating it. From the very beggining…
1 Global New Employee Orientation Workshop Welcome.
TEAM RAM MA1N0103 陳乃華 MA1N0206 Anja Išek MA1N0245 Michel Sung.
HealthPartners Clinical Indicators Communication Toolkit HealthPartners Communication Toolkit HealthPartners is pleased to provide you with.
Improving the competitiveness of the pharmaceutical industry Dominique Limet Senior Vice-President and Area Director Southern and Eastern Europe.
Inspired from Life Vision “To be most admired Scientifically driven Global Player in Next Generation Pharmaceutical & wellness Industry in 10 Years”
Dr. José M. Millán, PhD Deputy Director of CIBERER Universitary Hospital La Fe, Valencia, Spain Barriers and Challenges in Rare Diseases Research Centre.
Organized Diagnostic Assessment Demonstration Projects Organized Diagnostic Assessment Demonstration Projects Grand River Regional Diagnostic Assessment.
Introduction to The Cmed Group. About Cmed 2 Cmed Group Cmed Group is an innovative clinical trials services and advanced software provider that includes.
The Innovative Medicines Initiative (IMI) High level the IMI Concept, Strategic Research Agenda and Call topics Eva Lindgren.
Einari Kanerva founder and CEO Its My Life – Also in Corporate Wellness.
© Datamonitor the home of Business Intelligence intuitive deliveryexpert analysisquality data © Datamonitor.
Managing Medical R&D Defining and Realizing Clinical and Commercial Value David J. Wierz Senior Director Commercial Investment & Pricing Strategy Wyeth-Ayerst.
Global Corporate Citizenship Outcomes of WEC Sessions with the Financial and NGO Communities Jack S. Kace 
The Pharma Industry Industry sales: $346B with 42% growth during the past five years Future growth: 8-10% growth per year; largest companies to grow more.
Veiovis LifeSciences Pvt Ltd
Managing Innovation Evista Case Morgane … Maël Bourguignon Jonathan Calvet Axel Caborderie.
INAUGURAL NI AHP CONFERENCE 2013: Wednesday, 23 October Wednesday, 23 October, Lagan Valley Island, Lisburn “AHP’s – Transforming Your Care”
ODT-0147 (StudiVZ) Social Networking – Best practices
Patents and Medicines: How the system has discouraged innovation and reduced patient access to benefits of knowledge GREG PERRY Director General, EGA World.
Use of Atypical Antipsychotic Drugs by Children and Adolescents in the United States: A Retrospective Cohort Study Lesley H. Curtis, PhD Center for Clinical.
The Innovative Medicines Initiative A winning case for Joint Technology Initiative Status.
PUTTING THE PATIENT AT THE CENTER OF HEALTHCARE RESEARCH Towards a more inclusive model.
Strictly confidential How to achieve sustainability in rapidly changing environment? Pavle Marjanović, Country Manager for Actavis Republic of Serbia and.
The Pharmaceutical Composition Methodology described in this presentation has been developed to improve controlled drug delivery through site specific.
Zone for health, comfort and longevity! ZONA PHARMA BULGARIA September, 2015.
Cegedim Relationship Management Key Perspectives on Customer Databases November 2013.
Changes in Antipsychotic Pharmacotherapy and Healthcare Costs Following a New Diagnosis of Diabetes among Patients with Schizophrenia Douglas L. Leslie,
“Journey of a Drug” From Test Tube TO Prescribing Physician.
The Role of Patents, Universities, and Non-Profits in the Promotion of Health Care Access Nina Gandhi.
India – The Pharma Advantage Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Tokyo –
Jamjoom Pharmar (re-do the web) Project. Welcome to Novartis Fighting to end leprosy. 3.World. 4.Novartis.
Andy Passey September 23rd 2003 Advanced Wound Management in Europe: Market Overview and Critical Success Factors © 2003 Frost & Sullivan. All rights reserved.
The pharmaceutical market in Europe
Clinical Trials.
1 Promotion in Management and Research Tracks in Industry Magdalena Alonso-Galicia, PhD Cardiovascular Diseases Department Merck Research Laboratories.
Quality patients value sustainability partnership Value of generic medicines.
Quetiapine Fumarate Quetiapine Fumarate is an atypical antipsychotic used in the treatment of schizophrenia, bipolar I mania, bipolar II depression, bipolar.
Pharmacological management of delirium
Economics of Pharmaceutical Regulation in the Mediterranean: the case of Spain and Italy Joan Costa Font LSE.
SWOT analysis.
Psycho-oncology A physician’s guide.
Providing Hope to Patients and their Families Around the World!
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
Community Pharmacy: Sharing Our Vision
America’s Holistic Doctor The U.S. ranks dead last in preventable deaths among the 19 leading industrialized nations! We’re clearly off target in our approach.
INTERNATIONAL CONFERENCE ON PHARMACEUTICAL RESEARCH AND DEVELOPMENT
Changing the Game for Sjögren's Patients
Effective and humane care for all with mental, neurological,
Treatment-Resistant Schizophrenia
YONDELIS®: Giving Patients More Time
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
STRATEGIC ACTION IN HEALTH (AES)
Presentation transcript:

ADAMED Laboratorios SLU * Dedicated in body and mind

“Instead of a passive waiting for what future will bring us, we belive in a possibility of creating it. From the very beggining… This philosophy has been inspiring us till now. We hope it will be also yours from tomorrow.”

Adamed Spain – “a dream come true” ADAMED Laboratorios S.L.U. (Spain) is going to be a dynamic and innovative pharmaceutical company focus on CNS specialists an CNS pathologies in order to create add- value services and high quality products that represents a benefit for population. the words (october 2008) OBJECTIVES:

Adamed Spain Young company (average experience: 12 years in Spanish Market) R&D Support of Adamed Poland Innovative beyond products…specialist and patients contacts Specialized in SNC specialists (complicate Area) Gives high quality solutions Dynamic and Flexible Focused but with expansion expectations Characteristics:

Adamed Spain – “a dream come true” Specialized in Specialist: Focus on CNS specialists (psychiatrist and neurologist) focus on: – Schizophrenia Units – Bipolar Disease Units – Addictions Units – Parkinson Units Our identity: quality and add-value services – Products manufactured in Europe – Closing work with Scientific societies, be a referent on CNS market FACTS:

Adamed Products PRODUCTMOLECULELAUNCH DATE Topiramate (Antiepileptic drug) April 2009 Quetiapine (Antipsychotic drug) April 2009 Lamotrigine (Antiepileptic- Mood Stabilaser) June 2009 Venlafaxine (Dual Antidepressant) May 2009 Pramipexol e (Antiparkinsonian drug) Sept Clozapine (Antipsychotic drug) March 2011 Olanzapine (Antipsychotic drug) 25 th of April 2011

Adamed Evolution since launch 142% 151%

Adamed Spain – “a dream come true” Focus on CNS Specialist with a high positioning with the KOL of both societies. Recognised high-cooperation with Health Authorities pharma company Developing projects closed to medical societies: – Suicide Recommendations – SEP. SEPB- FEPSM – Fornes Project – Book for BD patients and family – Best in Class Awards for Neuro Specialist Awards received: – Launching Acomicil: Diario Médico – Book for BD patients and family FACTS:

Projects developed with CNS specialist Academia de Semiología “Recommendations for preventing and managing Suicidal behaviors” ACO-TEXT Trial: Evaluating adherence to treatment sending daily SMS to patients with addictions Neuro Best in Class Awards

Adamed launching Projects developed with CNS specialist

Strategic Plan Consolidate Adamed as a reference company for CNS Be a reference for the CNS specialists Support for patients and their families with information programs Simplicity and dynamism as a basis for the company strategy: – Working team – Pharma business, market and customer Knowledge – Value of well-done work Objectives:

Adamed Spain belongs to Adamed Group POLAND 1986 SPAIN (september 2008)

Some data… people working in Adamed Poland API, FP facilities (incl. Polfa and Agropharm adcquisitions) 25 patents 475 salesforce / 100 people working in R&D 150 M€ Polish market turnover after mergers / 20 M€ export sales Introduced in many areas: cardio, CNS, gastro, respi, OTC… New chemical entities: oncology, diabetes, CNS Philosophy: “From generic to innovative pharma”

History of innovation in Adamed PRIORITY AREAS OF OUR R &D: PRIORITY AREAS OF OUR R &D: Research of Innovative drugs Metabolic Diseases Metabolic Platform Cancer Diseases Oncology Platform Neuropsychiatry Platform CNS Diseases